ArticleJournal of the American Academy of Dermatology2013

Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia.

Livia Delgado et al.PubMed ↗Publisher ↗

No numbers read from the abstract.